Summary
Becton, Dickinson and Company (BD) filed a Form 8-K on March 13, 2015, to provide updated financial information related to changes in its reportable operating segments. Effective October 1, 2014, BD realigned its organizational structure into two primary business segments: BD Medical and BD Life Sciences. The BD Life Sciences segment now encompasses the former BD Diagnostics and BD Biosciences segments, reflecting a strategic shift to better align with its customer-focused solutions strategy. This filing does not introduce new events beyond the previously filed Form 10-K for the fiscal year ended September 30, 2014, but rather updates specific sections within that report (Item 7 and Item 8) to reflect the new segment reporting structure. Investors should note that comparative results under this new structure began to be reported with the Form 10-Q for the quarter ended December 31, 2014. This 8-K serves to provide clarity and updated disclosures regarding segment performance and resource allocation decisions.
Key Highlights
- 1BD has reorganized its business into two primary segments: BD Medical and BD Life Sciences, effective October 1, 2014.
- 2The BD Life Sciences segment now comprises the former BD Diagnostics and BD Biosciences businesses.
- 3This organizational change is driven by a strategy to better complement the company's customer-focused solutions.
- 4The filing provides updated financial information within the company's Form 10-K for the fiscal year ended September 30, 2014.
- 5Specific updated sections include Management's Discussion and Analysis (Item 7) and Financial Statements (Item 8).
- 6The company assesses segment performance and allocates resources based on operating income.
- 7This 8-K filing does not reflect events occurring after the initial 10-K filing, other than the segment reporting update.